Why the study?
Diabetic nephropathy is one of the most serious complications of diabetes mellitus, prompting the need to critically discuss available data on its pharmacological management.
Do pharmacological agents like RAS inhibitors, SGLT-2 inhibitors, and GLP-1 receptor agonists improve outcomes in patients with diabetic nephropathy?
Do pharmacological agents like RAS inhibitors, SGLT-2 inhibitors, and GLP-1 receptor agonists improve outcomes in patients with diabetic nephropathy?
This review highlights the cornerstone role of RAS inhibitors and the promising benefits of SGLT-2 inhibitors and GLP-1 receptor agonists in managing diabetic nephropathy and reducing cardiovascular events.
Answers are grounded in this paper and cite their sources.
Supports guideline-directed management of diabetic nephropathy; leaves open optimal combinations, sequencing, and staging in prospective trials.
INTRODUCTION: Diabetes mellitus (DM) is one of the most common diseases worldwide. Its adverse effects on several body organs, have made treatment of DM a priority. One of the most serious complications of DM is diabetic nephropathy (DN). OBJECTIVE: The aim of this review is to critically discuss available data on the pharmacological management of DN. METHODS: A comprehensive review of the literature was performed to identify studies assessing the impact of several drug classes on DN. RESULTS: Several studies have been conducted in order to find a novel and effective treatment of DN. So far, the cornerstone therapy of DN consists of renin-angiotensin system (RAS) inhibitors, agents that decrease the synthesis of intrarenal angiotensin II or block its receptors. Their antiproteinuric and antihypertensive effects can not only decelerate the progress of DN but prevent its onset as well. Novel antidiabetic drugs, such as sodium-glucose cotransporter 2 inhibitors (SGLT-2i) and glucagon-like peptide- 1 receptor agonists (GLP-1 RA), are promising agents in the therapy of DN, due to their positive effect on renal and cardiovascular adverse events. From lipid-lowering agents, atorvastatin improves DN up to stage 3 and substantially reduces CVD. CONCLUSION: RAS inhibitors, SGLT-2i and GLP-1 agonists were found to be beneficial for the treatment of DN. Larger renal trials are needed in order to incorporate these drugs into the first line treatment of DN.
No takes yet. Share an insight, caveat, or question.
Papademetriou et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: